TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
In upcoming news, TargaGenix is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City. Learn more and register to attend the conference at www.nyconcologyconference.com.